High-Level Overview
暂无分享,去创建一个
[1] K. J. Craik,et al. The nature of explanation , 1944 .
[2] A. Turing. The chemical basis of morphogenesis , 1952, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.
[3] H. Simon,et al. Rational choice and the structure of the environment. , 1956, Psychological review.
[4] R. W. White. Motivation reconsidered: the concept of competence. , 1959, Psychological review.
[5] H. Simon,et al. Motivational and emotional controls of cognition. , 1967, Psychological review.
[6] G. Johansson. Visual perception of biological motion and a model for its analysis , 1973 .
[7] T. Dexter,et al. In vitro duplication and ‘cure’ of haemopoietic defects in genetically anaemic mice , 1977, Nature.
[8] Rodney A. Brooks,et al. A Robust Layered Control Syste For A Mobile Robot , 2022 .
[9] B. Vogelstein,et al. Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.
[10] V. Broudy,et al. Stem cell factor and hematopoiesis. , 1997, Blood.
[11] Alan Bundy,et al. On Automating Diagrammatic Proofs of Arithmetic Arguments , 1999, J. Log. Lang. Inf..
[12] T. Shallice,et al. CONTENTION SCHEDULING AND THE CONTROL OF ROUTINE ACTIVITIES , 2000, Cognitive neuropsychology.
[13] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[14] G. Mcmahon,et al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. , 2000, The Journal of investigative dermatology.
[15] Kenji Nakamura,et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis , 2000, Oncogene.
[16] Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.
[17] Aaron Sloman,et al. Evolvable Biologically Plausible Visual Architectures , 2001, BMVC.
[18] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[19] Daniel Polani,et al. Meaningful Information, Sensor Evolution, and the Temporal Horizon of Embodied Organisms , 2002 .
[20] B. Druker,et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Demetri,et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. , 2002, Human pathology.
[22] C. Der,et al. Ras Family Signaling: Therapeutic Targeting , 2002, Cancer biology & therapy.
[23] N. Pryer,et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. , 2003, Molecular cancer therapeutics.
[24] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Van Cutsem,et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] K. Adolph. Learning to learn in the development of action , 2005 .
[28] E. Jablonka,et al. Evolution in Four Dimensions: Genetic, Epigenetic, Behavioral, and Symbolic Variation in the History of Life , 2005 .
[29] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[31] M. Boden,et al. Mind As Machine: A History of Cognitive Science Two-Volume Set , 2006 .
[32] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[33] S. Harnad. Symbol grounding problem , 1991, Scholarpedia.
[34] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Baccarani,et al. Imatinib mesylate in the treatment of hematologic malignancies , 2007, Expert opinion on biological therapy.
[36] K. Owzar,et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts) , 2007 .
[37] P. Neven,et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy , 2008, Breast Cancer Research and Treatment.
[38] K. Owzar,et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] John McCarthy. The well-designed child , 2008, Artif. Intell..
[40] D. Dennett,et al. The Extended Phenotype: The Long Reach of the Gene , 2008 .
[41] J. Fletcher,et al. Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma , 2008, Clinical Cancer Research.
[42] C. Antonescu,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. D. Van den Abbeele,et al. Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Aaron Sloman,et al. Architectures, Architecture-Schemas, And The New Science of Mind. 1 , 2008 .
[45] F. Craig,et al. Flow cytometric immunophenotyping for hematologic neoplasms. , 2008, Blood.
[46] Ben S. Wittner,et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.
[47] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[48] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[49] H. Kantarjian,et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. , 2009, Leukemia research.
[50] M. Heinrich,et al. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.
[51] C. Antonescu,et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. , 2010 .
[52] M. Tsao,et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer , 2010, Cancer.
[53] C. Horak,et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] G. Giaccone,et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.
[55] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[56] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[57] Takashi Ikegami,et al. Chemical Basis for Minimal Cognition , 2010, Artificial Life.
[58] C. Der,et al. Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.
[59] M. Heinrich,et al. Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.
[60] J. Blay. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. , 2011, Cancer treatment reviews.
[61] K. O'Byrne,et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. , 2011, The Lancet. Oncology.
[62] M. Kris,et al. A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[63] F. Cappuzzo,et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] D. Sargent,et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.
[65] M. Heslin,et al. Soft Tissue Sarcoma, Version 1.2021 Featured Updates to the NCCN Guidelines , 2022 .
[66] Carlos Gershenson,et al. Living is Information Processing: From Molecules to Global Systems , 2012, Acta Biotheoretica.